Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

Background Tocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients. Methods A multicenter, single-arm, hypothesis-driven trial was planned, according to a phase 2 design, to study the effect of...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of translational medicine Ročník 18; číslo 1; s. 405 - 11
Hlavní autoři:	Perrone, Francesco, Piccirillo, Maria Carmela, Ascierto, Paolo Antonio, Salvarani, Carlo, Parrella, Roberto, Marata, Anna Maria, Popoli, Patrizia, Ferraris, Laurenzia, Marrocco-Trischitta, Massimiliano M., Ripamonti, Diego, Binda, Francesca, Bonfanti, Paolo, Squillace, Nicola, Castelli, Francesco, Muiesan, Maria Lorenza, Lichtner, Miriam, Calzetti, Carlo, Salerno, Nicola Duccio, Atripaldi, Luigi, Cascella, Marco, Costantini, Massimo, Dolci, Giovanni, Facciolongo, Nicola Cosimo, Fraganza, Fiorentino, Massari, Marco, Montesarchio, Vincenzo, Mussini, Cristina, Negri, Emanuele Alberto, Botti, Gerardo, Cardone, Claudia, Gargiulo, Piera, Gravina, Adriano, Schettino, Clorinda, Arenare, Laura, Chiodini, Paolo, Gallo, Ciro
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	London BioMed Central 21.10.2020 BioMed Central Ltd Springer Nature B.V BMC
Témata:	Adult Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - therapeutic use Betacoronavirus - drug effects Betacoronavirus - immunology Biomedical and Life Sciences Biomedicine Care and treatment Clinical trials Cohort Studies Combination strategies Consent Coronavirus Coronavirus Infections - drug therapy Coronavirus Infections - epidemiology Coronaviruses COVID-19 Cytokines Drug dosages Female Humans Hypotheses IL-6 Immunosuppressive agents Inflammation Interleukin 6 Interleukins Italy - epidemiology Lethality Male Medicine/Public Health Middle Aged Monoclonal antibodies Mortality Off-Label Use Pandemics Phase 2 Pneumonia Pneumonia, Viral - drug therapy Pneumonia, Viral - epidemiology Population Registration SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Statistical analysis Steroid hormones Survival Tocilizumab Toxicity Treatment Outcome Validation Studies as Topic Variables Ventilation Italy COVID-19 Pneumonia Coronavirus Tocilizumab Mortality Phase 2 Safety IL-6
ISSN:	1479-5876, 1479-5876
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!